Kenvue (NYSE:KVUE) Price Target Lowered to $21.00 at UBS Group

Kenvue (NYSE:KVUE) had its price objective reduced by UBS Group from $23.00 to $21.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. UBS Group’s target price points to a potential upside of 4.27% from the stock’s current price.

Other analysts also recently issued reports about the company. Citigroup lowered their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $21.00 to $26.00 in a report on Monday, January 6th. Barclays cut their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th. Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research note on Monday. Finally, JPMorgan Chase & Co. raised their target price on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Kenvue has an average rating of “Hold” and a consensus price target of $22.92.

Kenvue Price Performance

NYSE:KVUE traded up $0.34 on Friday, reaching $20.14. 4,313,425 shares of the company’s stock traded hands, compared to its average volume of 12,214,764. The stock has a 50-day simple moving average of $21.61 and a 200-day simple moving average of $21.93. Kenvue has a 12 month low of $17.67 and a 12 month high of $24.46. The firm has a market cap of $38.61 billion, a PE ratio of 36.54, a P/E/G ratio of 2.05 and a beta of 1.45. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. Equities research analysts forecast that Kenvue will post 1.14 earnings per share for the current year.

Hedge Funds Weigh In On Kenvue

Several large investors have recently made changes to their positions in KVUE. Leo Wealth LLC raised its position in shares of Kenvue by 0.3% in the third quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock worth $3,507,000 after acquiring an additional 481 shares during the period. Alerus Financial NA increased its stake in shares of Kenvue by 0.3% during the third quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after purchasing an additional 491 shares in the last quarter. Kiley Juergens Wealth Management LLC lifted its holdings in Kenvue by 1.9% in the 4th quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock valued at $579,000 after purchasing an additional 500 shares in the last quarter. Principle Wealth Partners LLC boosted its stake in Kenvue by 3.7% during the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock worth $303,000 after buying an additional 500 shares during the last quarter. Finally, Wolff Wiese Magana LLC raised its holdings in shares of Kenvue by 0.7% in the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock valued at $1,781,000 after buying an additional 501 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.